biOasis Technologies Inc. (TSX:V.BTI) announces it has been named one of the 2012 TSX Venture 50® companies. The TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada's junior stock exchange.

biOasis Technologies Inc. (TSX:V.BTI) announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin®) in animal models of breast cancer metastasis in the brain. The studies at TTUHSC will be conducted under the direction of Drs. Quentin Smith and Paul Lockman – both recognized experts in the blood-brain barrier and in evaluating drug delivery to the central nervous system for the treatment of brain tumors.

biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) – is pleased to announce that it has Brisco Capital Partners Corp. (“Brisco”) to provide investor relations, subject to regulatory approval. Brisco will initiate and maintain contact with the financial community, shareholders, investors and other stakeholders for the purpose of increasing awareness of the Company and its activities. Brisco takes a full service approach to investor relations and provides creative investor relations’ programs for Canadian public companies.